Issues with supply of adrenaline auto injectors

British Society of Allergy and Clinical Immunology (BSACI) statement on limited supply of adrenaline auto injectors for allergy patients

Supply of adrenaline auto injectors remains a major issue affecting our patients. We have been in regular communication with the DHSC medicines supply team as well as the different manufacturers to understand the situation better. We are expecting formal communication from DHSC very soon, but in advance of that, wanted to let you know the following:

  • There are limited supplies of Emerade 150 microgram pens currently available, further supplies are expected early October. Bausch and Lomb have confirmed they expect supplies of Emerade 500 microgram to be available week commencing 23 September, and supplies of Emerade 300 microgram to be available early October.
  • Mylan have produced a statement relating to their ongoing challenges with manufacturing at their US plant. They have assigned a prescription validation process for EpiPen 0.3mg, meaning patients can obtain up to a maximum of two EpiPen 0.3mg AAIs per prescription. They have now extended the prescription validation process to include EpiPen Jr 0.15mg. This process is detailed on the BSACI website, it is designed to ensure supplies are managed equitably.
  • ALK-Abello Ltd also currently have supplies of Jext 150 microgram and 300 microgram pens available. Due to the supply issues affecting other brands, to support and maintain an overall adequate supply, ALK has obtained acceptance from the MHRA to extend the use of specific lot (batch) numbers of Jext® 150 mcg and Jext® 300 mcg auto-injectors, beyond the labelled expiry date by four months. Further details are posted on the news section of the BSACI website.